Targets › MICA
2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Mar 2027.
Widely expressed membrane-bound protein which acts as a ligand to stimulate an activating receptor KLRK1/NKG2D, expressed on the surface of essentially all human natural killer (NK), gammadelta T and CD8 alphabeta T-cells. Up-regulated in stressed conditions, such as viral and bacterial infections or DNA damage response, serves as signal of cellular stress, and engagement of KLRK1/NKG2D by MICA triggers NK-cells…. (UniProt, Q29983)
Open in Phaseline: the race on MICA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Cullinan Therapeutics | CLN-619 Anti-MICA/MICB monoclonal antibody | MICA, MICB | Phase 1 | Advanced Solid Tumor; Multiple Myeloma | Mar 2027 |
| D2M Biotherapeutics | DM919 Anti-MICA/MICB monoclonal antibody | MICA, MICB | Phase 1 | Advanced Solid Tumor | – |
Advanced Solid Tumor (2) Multiple Myeloma (1)
mixed (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.